Quantitative assessment of PD-L1 as an analyte in immunohistochemistry diagnostic assays using a standardized cell line tissue microarray-Reference-Cited by-同舟云学术

Quantitative assessment of PD-L1 as an analyte in immunohistochemistry diagnostic assays using a standardized cell line tissue microarray

Published:2019-08-13 Issue:1 Volume:100 Page:4-15
ISSN:0023-6837
Container-title:Laboratory Investigation
language:en
Short-container-title:Lab Invest

Author:

Martinez-Morilla Sandra,McGuire John,Gaule Patricia,Moore Lauren,Acs Balazs^ORCID,Cougot Delphine,Gown Allen M.,Yaziji Hadi,Wang Wei-Lien,Cartun Richard W.,Hornick Jason L.,Sholl Lynette M.,Qiu Jingxin,Mino-Kenudson Mari^ORCID,Yi Eunhee S.,Beasley Mary Beth,Merrick Daniel T.,Ambaye Abiy B.,Zhang Zhong J.,Walker Jill,Rimm David L.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Molecular Biology,Pathology and Forensic Medicine

Link

http://www.nature.com/articles/s41374-019-0295-9.pdf

Reference26 articles.

1. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455–65.

2. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–54.

3. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515:563–7.

4. Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387:1540–50.

5. Horn L, Spigel DR, Vokes EE, Holgado E, Ready N, Steins M, et al. Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057). J Clin Oncol. 2017;35:3924–33.

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pretreatment CD8+PD-1+ to CD4+PD-1+ ratio is associated with the prognosis of advanced melanoma patients treated with PD-1 inhibitors;Melanoma Research;2024-04-22

2. Immunotherapy for advanced non-small cell lung cancer with negative programmed death-ligand 1 expression: a literature review;Translational Lung Cancer Research;2024-02

3. Review of immune checkpoint blockade and PD-L1 testing in breast cancer;Diagnostic Histopathology;2024-02

4. Digital spatial profiling of melanoma shows CD95 expression in immune cells is associated with resistance to immunotherapy;OncoImmunology;2023-09-27

5. p53 as Exemplar Next-Generation Immunohistochemical Marker: A Molecularly Informed, Pattern-Based Approach, Methodological Considerations, and Pan-Cancer Diagnostic Applications;Applied Immunohistochemistry & Molecular Morphology;2023-07-21